Albany, NY -- (SBWIRE) -- 04/01/2020 -- DelveInsight launched a new report on Parkinson's Disease Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report

1. The total diagnosed Parkinson's Disease prevalent population in the 7MM is expected to rise to 3,284,084 in 2030, during the study period [2017–2030].
2. The highest diagnosed Parkinson's Disease prevalent population was in the United States.
3. Males are more prominent for developing Parkinson's Disease in comparison to female.
4. Primary Parkinsonism or Idiopathic Parkinson's cases are prominent in comparison to Secondary or atypical parkinsonism.

Key benefits of the report
1. Parkinson's Disease market report covers a descriptive overview and comprehensive insight of the Parkinson's Disease epidemiology and Parkinson's Disease market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Parkinson's Disease market report provides insights into the current and emerging therapies.
3. Parkinson's Disease market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Parkinson's Disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Parkinson's Disease market.

Request for sample pages

There is currently no cure, but Parkinson's Disease treatments are available to help relieve the symptoms and maintain the quality of life. Parkinson's Disease treatments include supportive therapies (physiotherapy), medication, and surgery (for some people). The medication can be used to benefit the main symptoms of Parkinson's disease, such as shaking (tremors) and movement problems. Three main types of medication are- Carbidopa-levodopa, Carbidopa-levodopa infusion, and Dopamine agonists.

The present Parkinson's Disease treatment options include medication, surgery, complementary and supportive therapies. The approved medication therapies are categorized into seven groups that include Levodopa, Carbidopa-levodopa infusion (Duodopa), Dopamine agonists (Mirapex, Requip, Neupro), MAO B inhibitors (Zelapar, Azilect, Xadago), Catechol O-methyltransferase (COMT) inhibitors (Tasmar, Comtan), Anticholinergics (Cogentin, Artane), and Amantadine.

The most frequently prescribed combination drugs are carbidopa/levodopa (cocareldopa [sinemet, pharmacopa, atamet]) and benserazide/levodopa (co-beneldopa [Madopar]). More recently, continuous intestinal infusion of levodopa gel (Duodopa [AbbVie Limited]) has shown to be effective in terms of decreasing severe motor fluctuations when compared to oral levodopa. However, this treatment is currently prohibitively expensive for widespread use. Levodopa with a DOPA decarboxylase inhibitor is usually a first-line treatment option for Parkinson's disease.

The present treatment options include medication, surgery, complementary and supportive therapies (such as diet, exercise, physical therapy, occupational therapy, and speech therapy). The approved medication therapies are categorized into seven groups that include Levodopa, Carbidopa-levodopa infusion (Duodopa), Dopamine agonists (Mirapex, Requip, Neupro), MAO B inhibitors (Zelapar, Azilect, Xadago), Catechol O-methyltransferase (COMT) inhibitors (Tasmar, Comtan), Anticholinergics (Cogentin, Artane), and Amantadine.

The most frequently prescribed combination drugs are carbidopa/levodopa (cocareldopa [sinemet, pharmacopa, atamet]) and benserazide/levodopa (co-beneldopa [Madopar]). More recently, continuous intestinal infusion of levodopa gel (Duodopa [AbbVie Limited]) has shown to be effective in terms of decreasing severe motor fluctuations when compared to oral levodopa. However, this treatment is currently prohibitively expensive for widespread use. Levodopa with a DOPA decarboxylase inhibitor is usually a first-line treatment option for Parkinson's disease. For patients with advanced Parkinson's disease, most surgeries are preferred.

The launch of the emerging therapies is expected to significantly impact Parkinson's Disease treatment scenario in the upcoming years:-
Drugs covered
1. Apomorphine Infusion
2. Accordion Pill Carbidopa/Levodopa
3. APL–130277
4. P2B001
5. IPX203
6. LY03003
7. ABBV-951
And many others

The key players in Parkinson's Disease market are:
1. US WorldMeds LLC
2. Intec Pharma
3. Sunovion Pharma
4. Pharma Two B Ltd
5. Impax Laboratories
6. Luye Pharma
7. AbbVie
And many others

Table of contents
1. Key Insights
2. Parkinson's Disease Market Overview at a Glance
3. Parkinson's Disease Background and Overview
4. Parkinson's Disease Epidemiology and Patient Population
5. Country Wise Parkinson's Disease Epidemiology
5.1. United States Epidemiology
5.2. EU-5 Epidemiology
5.2.1. Germany
5.2.2. France
5.2.3. Italy
5.2.4. Spain
5.2.5. United Kingdom
5.3. Japan Epidemiology
6. Parkinson's Disease Treatment and Management
7. Unmet Needs
8. Parkinson's Disease Marketed Drugs
8.1. Key Cross of Marketed Drugs
8.2. Profiles of Some of the Marketed Drugs
8.3. Istradefylline (KW6002): Kyowa Kirin
8.4. Opicapone: BIAL
8.5. Gocovri: Adamas Pharmaceuticals
8.6. Xadago: Zambon SpA
8.7. Osmolex ER: Osmotica Pharmaceutical
8.8. Duopa (Duodopa, ABT-SLV187): AbbVie
8.9. Rytary: Impax Laboratories
8.10. Inbrija: Acorda Therapeutics
8.11. Nuplazid: ACADIA Pharmaceuticals Inc.
9. Parkinson's Disease Emerging Drugs
9.1. Key Cross of Emerging Drugs
9.2. Apomorphine Infusion: US WorldMeds LLC
9.3. Accordion Pill Carbidopa/Levodopa: Intec Pharma
9.4. APL–130277: Sunovion Pharma
9.5. P2B001: Pharma Two B Ltd.
9.6. IPX203: Impax Laboratories
9.7. LY03003: Luye Pharma
9.8. ABBV-951: AbbVie
9.9. NTCELL Implantation: Living Cell Technologies
9.10. Nilotinib: Novartis
9.11. Solriamfetol (JZP-110): Jazz Pharmaceuticals
9.11.1. Product Description
9.11.2. Other Developmental Activities
9.11.3. Clinical Development
9.12. VY-AADC: Neurocrine Biosciences/Voyager Therapeutics
9.13. OXB-102 (AXO-Lenti-PD): Axovant Sciences
9.14. ND0612: NeuroDerm
9.15. ITI-214: Intracellular Therapies
9.16. IRL752: Integrative Research Laboratories AB (IRLAB)
10. Parkinson's Disease 7 Major Market Analysis
11. Market Outlook: The United States
11.1. United States Market Size
11.2. Market Outlook: Europe
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. Spain
11.2.5. United Kingdom
11.3. Market Outlook: Japan
12. Market Drivers
13. Market Barriers
14. SWOT Analysis
15. Appendix
16. DelveInsight Capabilities
17. Disclaimer
18. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
info@delveinsight.com
+919650213330
SOURCE DelveInsight